Efficacy and safety of pazopanib, everolimus and nivolumab in patients with metastatic renal cell carcinoma: a real life study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jun 2022 Results of a subgroup analysis assessed clinical outcome of trial-eligible and trial-ineligible pts with mRCC presented at the 58th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Interim results (n=414; 30 Sep 2019) updated analysis presented at the 56th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2019 Third interim results (n=421) presented at the 55th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com